New hope for rare immune disease: drug combo shows promise in small study
NCT ID NCT07531069
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs—interferon-gamma monoclonal antibody and dexamethasone—in 22 adults with a severe immune condition called refractory secondary HLH. The goal was to see if the treatment helps patients recover and how safe it is. Participants received the drugs as part of their care and were monitored with blood tests and checkups for 8 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT REFRACTORY SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huadong Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer aims to reveal hidden immune activity in tumors and arteries
- New immune cell boost may shield kids from Post-Transplant infections
- New drug aims to tame dangerous immune reactions from cancer therapy
- New drug aims to calm dangerous immune storms in Still's and lupus patients
- Cord blood transplants offer hope for kids without a donor match
- Researchers launch study to unravel mysteries of rare immune disorder sHLH